Salvage lenvatinib/everolimus (LE) combination therapy after immune checkpoint inhibitor (ICI) and VEGFR tyrosine kinase inhibitor (TKI) for metastatic renal cell carcinoma (mRCC)

被引：0

作者：

Khorasanchi, Adam

Kwok, Christopher

Psutka, Sarah P.

Hinkley, Megan

Dason, Shawn

Yang, Yuanquan

Verschraegen, Claire F.

Gross, Evan

Orcutt, Delaney

Yin, Ming

机构：

[1] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH USA

[2] Univ Washington, Fred Hutchinson Canc Ctr, Seattle, WA USA

[3] Ohio State Univ, James Canc Ctr, Columbus, OH USA

[4] James Canc Hosp, Columbus, OH USA

[5] Solove Res Inst, Columbus, OH USA

[6] Univ Washington, Sch Med, Seattle, WA USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e16520

引用

页数：1